Lactobacillus rhamnosus GG and Necrotizing Enterocolitis (NEC)

This is an important and well-researched topic in neonatology. Here's what the current evidence suggests:

Efficacy — Likely Helpful

Lactobacillus rhamnosus GG (LGG) is one of the probiotic strains that has been studied for the prevention of necrotizing enterocolitis in preterm and very low birth weight infants. Multiple meta-analyses of randomized controlled trials have found that probiotic prophylaxis — including regimens containing LGG — reduces the risk of severe NEC (Stage II or III) and all-cause mortality in preterm infants.

The evidence is strongest for multi-strain probiotics, but LGG as a single strain has also shown benefit in several trials.

Safety — Generally Favorable, but Not Zero-Risk

In the vast majority of infants, LGG is well-tolerated and safe. However, there are important caveats:

• Case reports of sepsis have been documented with Lactobacillus probiotics (including LGG) in extremely preterm or immunocompromised infants, though this is exceedingly rare.
• The risk-benefit ratio is generally considered to favor use, but some neonatal intensive care units (NICUs) remain cautious, particularly for infants with:
  • Birth weight <750g (extreme low birth weight)
  • Central venous catheters in place
  • Severe immunosuppression
  • Congenital gastrointestinal anomalies
  • Known milk protein allergy

Bottom Line

The available evidence indicates that LGG is likely beneficial for preventing NEC in preterm infants, with a favorable safety profile overall. However, decisions about probiotic use in a NICU setting should always be made on a case-by-case basis by the treating medical team, weighing the specific infant's risk factors.

Important: If this question relates to a specific infant under medical care, please discuss with the neonatologist or pediatric gastroenterologist managing that infant's care. This information is not a substitute for professional medical advice.